Results 231 to 240 of about 119,519 (336)

Clinical and laboratory presentations of Janus Kinase II-positive patients in Saudi population

, 2014
Hafiz Malhan, Hasan Alzahrani, Ghada Elgohary, Tarek Owaidah, Muhammad Aslam, Said Mohamed   +5 more
openalex   +1 more source

Targeting MCL‐1 and MAPK overcomes venetoclax resistance in FLT3‐ITD‐positive AML cells harbouring activating PTPN11 (SHP‐2) mutations

British Journal of Haematology, EarlyView.
Summary Venetoclax (VEN)‐based therapies have improved the treatment of acute myeloid leukaemia (AML); however, the emergence of resistance remains a major limitation. Mutations in protein tyrosine phosphatase (PTP) non‐receptor type 11 (PTPN11) and FMS like tyrosine kinase 3 with internal tandem duplication (FLT3‐ITD) are common in resistant patients ...
Maximilian Fleischmann, Ole Hansen, Diana Voigtländer, Julia Bechwar, Lenny‐Joseph Schwietzer, Sanja Bahr, Ulf Schnetzke, Mike Fischer, Florian H. Heidel, Tina M. Schnöder, Jörg P. Müller, Andreas Hochhaus, Sebastian Scholl   +12 more
wiley   +1 more source

Janus kinase and calcineurin-inhibitor combination in anti-MDA5 dermatomyositis: No significant survival benefit but reassuring safety profile. [PDF]

J Intern Med
Pagis V, Astouati Q, Pacoureau L, Nguyen Y, Bay P, Roux A, Gallay L, Cottin V, Terrier B, Meyer A, Cerf C, Neuville M, Hervier B, Renaud A, Suzon B, Schleinitz N, Papo T, Priou P, Mekinian A, Ullmer A, Oehler E, Gensous N, Berezne A, Martin LS, Marhadour T, Martin M, Servettaz A, Samson M, Gilardin L, Charles P, Woessner J, Carmoi T, Dilly B, Mauhin W, Baillet N, Humbert S, Thoreau B, Lemaitre M, Pendu CL, Loiseau P, Quemeneur T, Blanchard E, Voermans N, Launay D, Nunes H, Benveniste O, Uzunhan Y, Allenbach Y.   +47 more
europepmc   +1 more source

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Janus Kinase Inhibitor: A Possible Cause of Hyperammonemic Encephalopathy? [PDF]

J Clin Neurol
Park JH, Kim DH.
europepmc   +1 more source

Image 5_Comparative risk of uveitis with Janus kinase inhibitors versus tumor necrosis factor inhibitors in ankylosing spondylitis and psoriatic diseases: a target trial emulation study.tiff

Wei-Hsuan Bai (22489609), Pei-Lun Liao (14277744), Yi-Chiao Bai (10322840), James Cheng-Chung Wei (6830936)   +3 more
openalex   +1 more source

Cytokine Milieu Relevant to Atopic Dermatitis Enhances Epidermal Trypsin‐Like Serine Protease Activity, Which Is Pharmacologically Suppressed in Human Keratinocytes

The Journal of Dermatology, EarlyView.
Shiori Onishi, Yohei Yasutomi, Onon Tsedendorj, Shin Morizane   +3 more
wiley   +1 more source

Opioids in breast cancer: Between analgesia and modulation of tumour progression

British Journal of Pharmacology, EarlyView.
Preclinical investigations consistently demonstrate that activation of μ‐opioid receptors and δ‐opioid receptors promote proliferation, migration, angiogenesis, epithelial‐mesenchymal transition, acquisition of cancer stem cell phenotypes, and chemoresistance.
Marianna Ciwun, Anna Tankiewicz‐Kwedlo, Dariusz Pawlak   +2 more
wiley   +1 more source

Janus Kinase Inhibitors During Pregnancy and Adverse Drug Reactions: A Pharmacovigilance Disproportionality Analysis in VigiBase. [PDF]

Clin Transl Sci
Abolhassani N, Noseda R, Dao K, Girardin FR, Bedussi F, Ceschi A, Panchaud A, Winterfeld U.   +7 more
europepmc   +1 more source

B Cell Acute Lymphoblastic Leukemia is Driven by Activating Janus Kinase Mutations Cooperating with Spi1 and Spib Deletions in a Murine Model

, 2020
Michelle Lim
openalex   +1 more source